Skip to main content

Foundation Frontiers: A Medical Education Webinar

Thursday, June 13, 2024
12:00 pm1:00 pm

In non-small cell lung cancer (NSCLC), targetable driver alterations include ALK*, RET**, and ROS1*** fusions. DNA-based and RNA-based next-generation sequencing each have advantages and drawbacks for detecting gene fusions. In this webinar, expert speakers will present their perspectives on fusion detection in NSCLC.

Attendees Will Learn:
- Summary of currently approved therapies for fusions in NSCLC.
- Methods and recommendations for fusion detection with comprehensive genomic profiling.
- The pros and cons of DNA and RNA sequencing for fusion detection.
- About fusion detection in the context of a hypothetical patient case.


Mark Socinski, MD
Executive Director (Thoracic Cancer), Medical Oncologist
AdventHealth Cancer Institute
Orlando, FL

Holli Dilks, PhD
Senior Director, Global Head of Field Medical
Foundation Medicine
Boston, MA

* Anaplastic lymphoma kinase (ALK)
** rearranged during transfection (RET)
*** ROS proto-oncogene 1, receptor tyrosine kinase (ROS1)